Document:

Exhibit

          Exhibit 10.2

CTI BIOPHARMA CORP.
AMENDMENT TO EMPLOYMENT AGREEMENT

This Amendment to Employment Agreement (this “Amendment”) is made by and between Adam R. Craig (“Executive”) and CTI BioPharma Corp., a Delaware corporation (the “Company” and together with Executive, the “Parties”) on the dates set forth below.
WHEREAS, the Parties previously entered into an Employment Agreement effective February 24, 2017 (the “Employment Agreement”); 
WHEREAS, the Company and Executive desire to amend certain provisions of the Employment Agreement, as set forth below.
NOW, THEREFORE, for good and valuable consideration, including, but not limited to, Executive’s continued employment with the Company, the Parties agree that the Employment Agreement is hereby amended as follows:
1.The Employment Agreement is hereby amended as follows:

A.The word “understands” is inserted between the phrases “the Executive” and “the Company” at the beginning of clause (vi) in Section 1.4. 

B.Section 3.2 is hereby replaced in its entirety with the following:
3.2    Incentive Bonus. Commencing with the Company’s 2017 fiscal year, the Executive shall be eligible to receive an incentive bonus for each fiscal year of the Company that occurs during the Period of Employment (“Incentive Bonus”). The Executive’s target Incentive Bonus amount for a particular fiscal year of the Company (the “Target Incentive Bonus”) shall equal Fifty-Five Percent (55%) of the Executive’s Base Salary paid by the Company to the Executive for that fiscal year; provided that the Executive’s actual Incentive Bonus amount for a particular fiscal year shall be determined by the Board (or a committee thereof) in its sole discretion, based on performance objectives (which may include corporate, business unit or division, financial, strategic, individual or other objectives) established with respect to that particular fiscal year by the Board (or a committee thereof). The Board (or a committee thereof) may, in its sole discretion, increase (but not decrease) the Executive’s Target Incentive Bonus percentage. For any fiscal year in which the Executive’s employment with the Company terminates before the end of such fiscal year, the Incentive Bonus corresponding to such fiscal year shall be pro-rated based on the number of days the Executive was employed with the Company during such fiscal year.  The Incentive Bonus, if any, corresponding to a particular fiscal year, will be paid at such time the Company pays bonuses to other executives of the Company, but in no event later than March 15 of the year following the applicable fiscal year for which such Incentive Bonus was earned.

C.The word “Executive” is inserted between the words “The” and “agrees” at the beginning of the second sentence in Section 3.4.

D.Section 5.5(a) is hereby replaced in its entirety with the following:
(a)  As used herein, “Accrued Obligations” means:

(i)    any Base Salary that had accrued but had not been paid (including accrued and unpaid vacation time) on or before the Severance Date;
(ii)    any Incentive Bonus for the previous fiscal year that had not been paid as of the Severance Date, provided that such Incentive Bonus will be pro-rated based on the number of days the Executive was employed by the Company during such fiscal year, in accordance with Section 3.2 above; and
(iii) any reimbursement due to the Executive pursuant to Section 4.2 for expenses reasonably incurred by the Executive on or before the Severance Date and documented and pre-approved, to the extent required by Company policy, in accordance with the Company’s expense reimbursement policies in effect at the applicable time.

E.Section 5.6 is hereby replaced in its entirety with the following:
5.6 Notice of Termination; Employment Following Expiration of Period of Employment.  Any termination of the Executive’s employment under this Agreement shall be communicated by written notice of termination from the terminating party to the other party. This notice of termination must be delivered in accordance with Section 18 and must indicate the specific provision(s) of this Agreement relied upon in effecting the termination. If the Executive delivers notice of non-renewal of the Period of Employment pursuant to Section 2, the Executive’s employment by the Company shall end at the expiration of the Period of Employment then in effect (unless otherwise agreed by the parties) and, in connection with such termination of employment, the Executive shall be entitled to the benefits specified in Section 5.3(a) but not (except as otherwise provided in the next sentence) the benefits specified in Section 5.3(b).  If the Company delivers notice of non-renewal of the Period of Employment pursuant to Section 2 and the Executive’s employment by the Company terminates at the end of the Period of Employment then the termination shall be treated as though it occurred immediately prior to the end of the Period of Employment and Section 5.3(b) shall apply in connection with such termination (for clarity, which shall continue to be subject to Sections 5.3(c) and 5.4).

F.The addresses provided in the notice provision in Section 18 are hereby replaced in their entirety with the following:
if to the Company:

CTI BioPharma Corp.          
3101 Western Avenue, Suite 800
Seattle, Washington  98121 
Attention: Chairman
with a copy (which shall not constitute notice) to:

Michael Nordtvedt
Wilson Sonsini Goodrich &Rosati, P.C.
701 Fifth Avenue, Suite 5100 
Seattle, WA 98104 
if to the Executive, to the address most recently on file in the payroll records of the Company.

2.Full Force and Effect. To the extent not expressly amended hereby, the Employment Agreement shall remain in full force and effect.
3.Entire Agreement. This Amendment, the Employment Agreement (as amended herein), and any other documents, exhibits or schedules referenced in the Employment Agreement constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof.
4.Governing Law. This Amendment will be governed by the laws of the State of Washington (with the exception of its conflict of laws provisions).
(signature page follows)

IN WITNESS WHEREOF, each of the Parties has executed this Amendment as of the date set forth below.
ADAM R. CRAIG                    CTI BIOPHARMA CORP.
By:    /s/ Adam R. Craig                By:    /s/ David H. Kirske            
Date:    October 30, 2018                     Name:    David H. Kirske            
    Title:    Chief Financial Officer            
    Date:    October 31, 2018Exhibit 10.1

 

AMENDMENT NO. 2 TO THE INPIXON 2018 EMPLOYEE
STOCK INCENTIVE PLAN

 

This Amendment No. 2 (the
“Amendment”) to the Inpixon 2018 Employee Stock Incentive Plan (the “Plan”) is made pursuant to Section
12 of the Plan. Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in
the Plan.

 

WHEREAS, the Plan
was approved and adopted by the board of directors (the “Board”) of Inpixon (the “Company”) on January
4, 2018 and approved by the stockholders of the Company on February 2, 2018;

 

WHEREAS,
Section 12.2 of the Plan provides that the Board may modify or amend the Plan in whole or in part and from time to time in such
respects as it deems advisable;

WHEREAS,
the Plan was amended by the Amendment No. 1 to the Plan, which did not contain any amendment that requires stockholder approval
and was approved and adopted by the Board on May 17, 2018;

WHEREAS, the Board
has determined that it is in the best interests of the Company and its stockholders to further amend the Plan as set forth below;

 

WHEREAS, the Board
approved this Amendment on October 5, 2018; and

 

WHEREAS, the stockholders
of the Company approved this Amendment on October 31, 2018.

 

NOW THEREFORE, the
Plan is amended as follows:

 

		1.	Section 1. Section 1 is hereby amended and restated with the following:

 

“Shares
Subject to the Plan.

Subject to an adjustment
in accordance with Section 8, the maximum number of shares which may be issued under the Plan shall be two million (2,000,000)
shares of Common Stock, par value $0.001 per share (the “Initial Limit”), of the Company (the “Shares”),
which shall automatically increase on the first day of each calendar quarter, beginning on April 1, 2018 and for each quarter thereafter
through October 1, 2028, by a number of shares of Common Stock equal to the least of (i) 1,000,000 Shares, (ii) twenty percent
(20%) of the outstanding Shares on the last day of the immediately preceding calendar quarter, or (iii) such number of Shares determined
by the Committee (the “Quarterly Increase”). The Company shall at all times while the Plan is in effect reserve such
number of shares of Common Stock as will be sufficient to satisfy the requirements of outstanding Awards granted under the Plan.
The Shares subject to the Plan shall be either authorized and unissued shares or treasury shares of Common Stock. If any Award
is forfeited, or if any Stock Option (and related Stock Appreciation Right, if any) terminates, expires or lapses for any reason
without having been exercised in full or shall cease for any reason to be exercisable in whole or in part, or if any Stock Appreciation
Right is exercised for cash, the unpurchased Shares subject to such Awards shall again be available for distribution under the
Plan. Subject to such overall limitations, the maximum aggregate number of Shares that may be issued in the form of Incentive Stock
Options shall not exceed the Initial Limit cumulatively increased on April 1, 2018 and on the first day of each quarter thereafter
by the Quarterly Increase.”

    

     

    

 

		2.	Section 4.2. Section 4.2 is hereby amended and restated with the following:

 

“Maximum Stock
Option Grant. With respect to Stock Options which are intended to qualify as Incentive Stock Options, the aggregate Fair Market
Value (determined as of the time the Stock Option is granted) of the Common Stock with respect to which Incentive Stock Options
granted to any participant (whether under this Plan or under any other stock option plan of the Company or its Subsidiaries) become
exercisable for the first time in any calendar year, may not exceed $100,000. The number of Shares for which any participant, in
any calendar year, may be granted Stock Options under the Plan not treated as Incentive Stock Options shall be limited to not more
than 150,000. Notwithstanding the forgoing, nothing contained in the Plan shall be construed to prohibit the grant of Stock Options
under the Plan to an Eligible Person by reason of such person holding Stock Options to purchase shares of Common Stock or any other
securities of the Company granted otherwise than under the Plan.”

 

		3.	Section 8. Section 8 is hereby amended and restated with the following:

 

“Adjustments
Upon Change in Capitalization.

In the event
of changes in the outstanding shares of Common Stock of the Company by reason of stock dividends, stock splits, reverse stock splits,
recapitalizations, mergers, consolidations, combinations or exchanges of shares, separations, reorganizations or liquidations,
the number and class of shares available under the Plan, the number and class of Shares or the amount of cash or other assets or
securities available upon the exercise of any Award granted hereunder and the number of Shares to be issued pursuant to an Award
shall be correspondingly adjusted, to the end that the participant’s proportionate interest in the Company, any successor
thereto or in the cash, assets or other securities into which Shares are converted or exchanged shall be maintained to the same
extent, as near as may be practicable, as immediately before the occurrence of any such event. Notwithstanding the foregoing, no
adjustment under this Section shall reduce the maximum number of Shares which may be issued under the Plan, the Quarterly Increase,
or reduce any limitations related to Incentive Stock Options. For example, if the Company effects a reverse stock split of its
outstanding Common Stock, the the number of Shares available upon the exercise of any Award shall be adjusted; however, the maximum
number of Shares available under the Plan shall not be correspondingly adjusted. All references in this Plan to “Common Stock”
from and after the occurrence of such event shall be deemed for all purposes of this Plan to refer to such other class of shares
or securities issuable upon the exercise or payment of Awards granted pursuant hereto.”

In all other respects, the
terms and conditions of the Plan shall remain the same.

 

[Signature page follows.]

 

    2

     

    

 

IN WITNESS WHEREOF, the Company has adopted
this Amendment, effective as of the 31st day of October, 2018.

 

 

	 	INPIXON
	 	 	 
		By:	/s/
    Nadir Ali
	 	Name:	Nadir
    Ali 
	 	Title:	Chief
    Executive Officer  

 

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]